Cook Medical has announced a strategic investment in the urology space via Zenflow, a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH).
“This investment reflects our confidence in the future of Zenflow and the Spring System technology. Zenflow is aligned with our core focus of developing minimally invasive technologies that restore flow,” said DJ Sirota, senior vice president of Cook Medical’s MedSurg division. “This type of agreement is yet another proof point to how Cook is changing to focus on our future as product innovators.”
With funding led by Cook, Zenflow closed an US$24 million series C financing round last month and included participation from existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners and others.
Funds will be used to support the company’s pre-market approval (PMA) submission as well as to prepare for commercialisation in order to set the stage for US Food and Drug Administration (FDA) approval of its Spring System, a minimally invasive treatment option for patients who suffer debilitating symptoms due to an enlarged prostate. The Spring System relies on a small spring-like coil to prop open the urethra, restoring its normal function while preserving the natural anatomy.
